Intuitive Surgical (ISRG) Shares Surge Following Thursday Freak-out
Tweet Send to a FriendGet Alerts ISRG Hot Sheet
Price: $470.30 -3.21%
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade ISRG Now!
Shares of Intuitive Surgical (NASDAQ: ISRG) surged on Friday, paring losses following a massive drop on Thursday afternoon. The concern relates to reports that the FDA is investigating the safety and use of the company's da Vinci robotic system. While the headline was frightening, analysts are urging investors to remain calm as the investigation appears to be "standard postmarket surveillance".
Goldman Sachs analyst David H. Roman said, "We acknowledge the risk that the FDA inquiry poses, the potential for increased volatility in ISRG shares, and uncertainty in how the clinical community will react to the FDA survey."
"At this point," continued Roman, "we see no evidence to derail our bullish thesis and see current levels presenting a compelling entry point."
Analysts at Cantor Fitzgerald went one step further and upgraded the stock to Buy, calling the selloff a "gross overreaction".
Goldman Sachs has a Buy rating on Intuitive Surgical with a price target of $715.
For an analyst ratings summary and ratings history on Intuitive Surgical (NASDAQ: ISRG) click here. For more ratings news on Intuitive Surgical click here.
Shares of Intuitive Surgical closed at $509.89 yesterday, with a 52 week range of $467.26-$594.89.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Goldman Sachs analyst David H. Roman said, "We acknowledge the risk that the FDA inquiry poses, the potential for increased volatility in ISRG shares, and uncertainty in how the clinical community will react to the FDA survey."
"At this point," continued Roman, "we see no evidence to derail our bullish thesis and see current levels presenting a compelling entry point."
Analysts at Cantor Fitzgerald went one step further and upgraded the stock to Buy, calling the selloff a "gross overreaction".
Goldman Sachs has a Buy rating on Intuitive Surgical with a price target of $715.
For an analyst ratings summary and ratings history on Intuitive Surgical (NASDAQ: ISRG) click here. For more ratings news on Intuitive Surgical click here.
Shares of Intuitive Surgical closed at $509.89 yesterday, with a 52 week range of $467.26-$594.89.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Goldman Sachs Downgrades InterXion Holding (INXN) to Neutral
- Deutsche Bank Raises PT on NetApp (NTAP) to $48
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Cantor Fitzgerald, Goldman Sachs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
